Enlivex Therapeutics Ltd. Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for ENLV, updated each market day.
ENLV AI Sentiment
AI sees no strong directional signal for Enlivex Therapeutics Ltd. Ordinary Shares stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Enlivex Therapeutics Ltd. Ordinary Shares
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Exchange
Market Cap
$12,715,427
Cap Tier
Employees
34
Listed Since
July 31, 2014
Website
ENLV Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ENLV Volatility
Enlivex Therapeutics Ltd. Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
